

# Questions spéciales de radioprotection (WRPR 3010)

## Imaging and proton therapy

Prof. Edmond Sterpin

# Objectives of the course



- Basics of radioprotection
- Imaging systems in radiotherapy
  - Description of the systems
  - Dosimetry
  - Advantages and disadvantages of the systems
  - Quality assurance
- Proton therapy
  - Generalities on proton therapy
  - Elements of the physics of nuclear reactions
  - State of the art of neutron dosimetry in patients
  - Considerations on the shielding of proton therapy devices
  - Problem of activation

## Course notes

- These slides
- Chapter 10 of IAEA recommendations of QA for imaging systems (only the main principles: what do we need to check? For which reasons?)
- Physics of proton therapy
- For information: papers on proton therapy shielding

# Basics of radioprotection


- Radiations do damage





# Basics of radioprotection

- Radiations do damage



A: linear extrapolation  
B: linear-quadratic extrapolation  
C: linear extrapolation with threshold

## Basics quantities

- The physical dose
- The equivalent dose in radiation protection
- The effective dose in radiation protection

# Absorbed dose

Expressed in the unit Gray [Gy]

$$1 \text{ Gy} = 1 \frac{\text{J}}{\text{kg}} = 1 \frac{\text{m}^2}{\text{s}^2}$$

**“In typical radiotherapy treatments, radiation doses are delivered in the range of 8 J/kg to 80 J/kg”**



**In comparison:**

**“To rise the temperature of water by 1 °C, requires an energy of 4200 J/kg (C<sub>p</sub> of water)”**

# Insufficiencies of the absorbed dose as a surrogate for biological effects

The effect of radiations is not linked only to the dose

Other features play a role, e.g. the density of ionizations


Thus, we introduce other quantities to **scale** the physical dose, according to the **biological effects** of radiations.

In radiotherapy, we use the so-called Relative Biological Effectiveness (RBE) --> leads to the concept of biological dose (in Gy)

In radioprotection, we use the **equivalent dose**. It is expressed in Sievert (Sv)

# Different particles do not cause the same damage to DNA for the same energy absorbed


## DNA effects of ionizing radiations



# Different particles do not cause the same damage to DNA for the same energy absorbed

LET: linear energy transfer

➔ Density of ionizations along a particle track



**Photons: low energy released per track**

**Alpha, Carbon ions...: more energy released per "track"**

**FIGURE 7.14**

Particle track structure for low-LET radiation (upper picture) and for  $\alpha$ -particles (lower picture). The circles represent the size of the nucleus of a typical mammalian cell. The tortuous nature of the (low-LET) secondary electron tracks are in complete contrast to the high-LET particles, of which only around *four* are required to deposit a dose of 1 Gy in that small volume. (From Goodhead, D. T., *Health Phys.*, 55, 231–240, 1988. With permission.)

## Concept of equivalent dose *in radiation protection*

**Equivalent dose** = absorbed dose \* radiation weighting factor ( $W_R$ ) in Sievert (Sv).

| Type                                               | Energy range   | $W_R$                               |
|----------------------------------------------------|----------------|-------------------------------------|
| Photons, electrons                                 | all            | 1                                   |
| Neutrons                                           | < 1 MeV        | $2.5 + 18.2\exp[-(\ln(E))^2/6]$     |
|                                                    | 1 MeV - 50 MeV | $5.0 + 17.0\exp[-(\ln(2E))^2/6]$    |
|                                                    | > 50 MeV       | $2.5 + 3.25\exp[-(\ln(0.04E))^2/6]$ |
| Protons                                            |                | 2                                   |
| Alpha, fission fragments,<br>heavy nuclei (Carbon) | all            | 20                                  |

# Insufficiencies of the equivalent dose as a surrogate for the *risk* of biological effects

The risk of developing a secondary cancer (or genetical mutation) will depend on the equivalent dose but also on the **type of organ irradiated**

In order to make comparable a given equivalent dose delivered to one organ to another dose delivered to another organ, we introduce the concept of **effective dose**

**Effective dose** =  $\sum_T D_{abs} * W_R * \text{tissue weighting factor } (W_T)$  in Sievert (Sv)

Where  $T$  loops over all tissues

| Tissue or organ | $W_T$ |
|-----------------|-------|
| Gonads          | 0.08  |
| Bone Marrow     | 0.12  |
| Colon           | 0.12  |
| Breast          | 0.12  |
| Skin            | 0.01  |




# Imaging systems in radiotherapy

Prof. Edmond Sterpin





# RT workflow



# RT workflow



**Imaging**

Contouring  
&  
Prescription

Treatment  
optimization

Treatment  
verification

Treatment  
delivery



CT scanner

# RT workflow



**Imaging**

Contouring  
&  
Prescription

Treatment  
optimization

Treatment  
verification

Treatment  
delivery



CT scanner

# RT workflow




Imaging

**Contouring  
&  
Prescription**





Treatment  
optimization

Treatment  
verification

Treatment  
delivery



# RT workflow



Dose prescription  
for the tumor:  
60 Gy

Lung limit:  
Mean dose < 20 Gy

Spinal cord limit:  
Max dose < 50 Gy

**Dose**  
quantifies the amount of  
energy deposited  
by the radiations per  
unit of mass  
(expressed in Gy).



# RT workflow




Imaging

Contouring  
&  
Prescription

**Treatment  
optimization**

Treatment  
verification


Treatment  
delivery




Optimization of the treatment plan  
to deliver an optimal dose distribution,  
conform to the prescriptions




# RT workflow




Treatment plan evaluation



Measurements




# RT workflow



The treatment is delivered in multiple fractions

# Where radiotherapy medical physics kicks in




This process must work!

And with accuracy!

# The deal of RT



**HIGHEST dose to tumor volume**  
**LOWEST dose to healthy tissues**




**Improved ballistics**

**Better choice of particles**


**Differential radiobiological effects**

**We can also impact tumor control curve (radiosensitization)**


## Patient changes



**PRE-R**



**Week 3**



**Week 5**

**Patient is still alive...**

Primary lung tumor



Mediastinal lymph nodes




Motion is a major source of  
geometric uncertainty

# The impact can be catastrophic, especially in PT

Day 0

Day 35



From Lomax (2006)



# Ensuring tumor local control in the presence of uncertainties

In radiotherapy, we use margins to ensure adequate irradiation of tumour cells. These margins include, among others, geometrical uncertainties (uncertainties on the position of the tumor)

The larger the margin, the smaller the therapeutic window

More imaging → reduced margins, reduced doses to healthy tissues, increased therapeutic window

But...

- Additional workload
- Additional doses from the imaging system itself



## Fan KV beam CT scanner




Simulation CT scan for contouring and treatment planning




CT on-rails for precise positioning and/or replanning strategies

**Fan KV beam CT scanner is the gold standard for image quantification and conservation of physical distances**


## Fan MV beam CT scanner (embedded in RT treatment unit)




## Flat panel 2D imagers (using MV beam)



## MV CBCT




## KV CBCT




# Rough comparison of imaging systems

Rule of thumb: imaging dose goes as first approximation with the square of the voltage






## FBCT and CBCT principles





Fan beam  
1D detector  
Volume acquired with multiple  
rotations (helicoïdal acquisition)



Cone beam  
2D detector  
Volume acquired in one rotation


# CBCT issues

- **Missing data (truncation)**
  - Detector field of view 25 cm
- **Scattered radiation**
  - Extra signal not from local anatomy
  - Adds noise !
- **Beam hardening**
  - Attenuation of patient smaller than expected
- **Ghosting**
  - High exposure signal gives residual extra signal later




## Scatter to primary ratio

# Scatter & Imaging Geometry




Cone Beam CT




Fan Beam CT

Scatter-to-primary ratio (SPR) in excess of 300% occur in lateral pelvic projection data occur for CBCT geometry


## Reduced field-of-view in CBCT systems



## Increase field-of-view




## Increase field-of-view



## Increase field-of-view


### Offset Detector



# Fan beam KVCT vs Cone beam KVCT



Cone Beam CT




Fan Beam CT

Cone Beam CT vs. Fan Beam CT: A  
Comparison of Image Quality and Dose  
Delivered Between Two Differing CT  
Imaging Modalities

Lawrence Lechuga<sup>1</sup>, Georg A. Weidlich<sup>2</sup>



# Comparison of imaging systems



JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 17, NUMBER 2, 2016

## Assessment of image quality and dose calculation accuracy on kV CBCT, MV CBCT, and MV CT images for urgent palliative radiotherapy treatments

Mareike Held,<sup>1</sup> Florian Cremers,<sup>2</sup> Penny K. Sneed,<sup>1</sup> Steve Braunstein,<sup>1</sup> Shannon E. Fogh,<sup>1</sup> Jean Nakamura,<sup>1</sup> Igor Barani,<sup>1</sup> Angelica Perez-Andujar,<sup>1</sup> Jean Pouliot,<sup>1</sup> and Olivier Morin<sup>1a</sup>  
Department of Radiation Oncology,<sup>1</sup> University of California San Francisco, CA, USA;  
Department of Radiation Oncology,<sup>2</sup> Universitätsklinikum Schleswig-Holstein, Lübeck, Germany  
Olivier.Morin@ucsf.edu

# Comparison of imaging systems

## Feasibility study on effect and stability of adaptive radiotherapy on kilovoltage cone beam CT


Poonam Yadav<sup>1,2,3</sup>, Velayudham Ramasubramanian<sup>3</sup>, Bhudatt R. Paliwal<sup>1,2</sup>

<sup>1</sup>Department of Human Oncology, University of Wisconsin, Madison, WI, USA

<sup>2</sup>Department of Medical Physics, University of Wisconsin, Madison, WI, USA

<sup>3</sup>Vellore Institute of Technology University, Vellore, Tamil Nadu, India

Received 7 February 2011  
Accepted 24 March 2011



Fan beam  
KVCT


Cone beam  
KVCT

Fan beam  
MVCT

# Metal artifacts


Metal artifacts in computed tomography for radiation therapy planning: dosimetric effects and impact of metal artifact reduction

Drosoula Giantsoudi<sup>1</sup>, Bruno De Man<sup>2</sup>, Joost Verburg<sup>1</sup>, Alexei Trofimov<sup>1</sup>, Yunnan Jin<sup>2</sup>, Ge Wang<sup>3</sup>, Lars Gjestebj<sup>4</sup> and Harald Paganetti<sup>1</sup>



**Figure 9.** Diagnostic kVCT scan (a) and MVCT scan (b) on the TomoTherapy Hi-Art system for a patient with metal implants in the spine (Reproduced with permission from Rong *et al* 2011. CC BY 3.0).

# Quantities for imaging doses



$CTDI_{100}$ : average dose imparted by a single axial acquisition to a standard 100 mm pencil chamber dosimeter inside a PMMA phantom

$$CTDI_{100} = \int_{-50mm}^{50mm} \frac{D(z)}{ST} dz \text{ where } ST \text{ is the slice thickness}$$

$$CTDI_w: 1/3CTDI_{100}^{central} + 2/3CTDI_{100}^{peripheral}$$

$$CTDI_{vol} = CTDI_w / PITCH \text{ (used for CT only)}$$

# Imaging doses

## COMPARISON OF RADIATION DOSES BETWEEN CONE BEAM CT AND MULTI DETECTOR CT: TLD MEASUREMENTS

Sangroh Kim<sup>1</sup>, Terry T. Yoshizumi<sup>2,\*</sup>, Greta Toncheva<sup>2</sup>, Sua Yoo<sup>3</sup> and Fang-Fang Yin<sup>3</sup>

<sup>1</sup>Medical Physics Graduate Program, Duke University, Durham, NC 27705, USA

<sup>2</sup>Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA

<sup>3</sup>Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA

Received September 8 2008, revised November 18 2008, accepted November 20 2008

**Table 3. Comparison of  $CTDI_w^{CBCT}$ ,  $CTDI_w^{CBCT}$  per 100 mAs,  $CTDI_{vol}^{MDCT}$ ,  $CTDI_{vol}^{MDCT}$  per 100 mAs and console displayed  $CTDI_{vol}^{MDCT}$  for the head and body phantoms.**

| Scan protocols | CBCT               |                    |                             | MDCT                |                                 |                     |                |
|----------------|--------------------|--------------------|-----------------------------|---------------------|---------------------------------|---------------------|----------------|
|                | Measurements (mGy) |                    |                             | Measurements (mGy)  |                                 | Console display     |                |
|                | $CTDI_w^{CBCT}$    |                    | $CTDI_w^{CBCT}$ per 100 mAs | $CTDI_{vol}^{MDCT}$ | $CTDI_{vol}^{MDCT}$ per 100 mAs | $CTDI_{vol}^{MDCT}$ | Difference (%) |
|                | This Study         | Song <i>et al.</i> |                             |                     |                                 |                     |                |
| Head           | $89.7 \pm 4.0$     | 83                 | $6.69 \pm 0.30$             | $137.0 \pm 7.4$     | $31.6 \pm 1.7$                  | 106.0               | 23             |
| Body           | $37.9 \pm 1.4$     | 54                 | $2.84 \pm 0.10$             | $74.3 \pm 5.3$      | $17.2 \pm 1.2$                  | 47.4                | 36             |

MDCT: conventional CT (multi-detector CT)

# Imaging doses

JR Sykes<sup>1</sup>, R Lindsay<sup>1</sup>, G Iball<sup>1</sup> and DI Thwaites<sup>1,2</sup><sup>1</sup>Medical Physics and Engineering, St James's Institute of Oncology, Leeds, UK<sup>2</sup>Institute of Medical Physics, School of Physics, University of Sydney, Australia

E-mail: jonathan.sykes@leedsth.nhs.uk

**Table 1:** Cone Beam dose measurements (similar to CTDI<sub>w</sub>) for standard imaging protocols on the Varian OBI and Elekta Synergy CBCT systems published in the UK Centre of Evidence Based Purchasing report [28]. Manufacturers recommended protocol settings may change over time based on the introduction of new technology or feedback from customers.

| Varian OBI Imaging Protocol | Dose (mGy) | Elekta Synergy Imaging Protocol | Dose (mGy) |
|-----------------------------|------------|---------------------------------|------------|
| Low Dose Head               | 2.8        | Low Dose Head                   | 1.4        |
| Standard Dose Head          | 5.6        | Medium Dose Head                | 5.4        |
| High Quality Head           | 27.8       | High Dose Head                  | 9.4        |
| Pelvis                      | 24.9       | Pelvis M10                      | 15.3       |
| Pelvis Spotlight            | 20.2       | Pelvis M15                      | 12.5       |
|                             |            | Pelvis M20                      | 13.7       |

**Table 2:** Monte Carlo calculated patient doses (cGy) for three anatomical sites for the Elekta Synergy CBCT system and the Varian OBI CBCT system. Doses reported are for the body i.e. not to a specific organ.

|                                      | Pelvis/Abdomen | Head and Neck | Chest     |
|--------------------------------------|----------------|---------------|-----------|
| Elekta XVI (Spezi <i>et al</i> ) [8] | 1.5 - 2.1      | 0.1 - 0.2     | 1.2 - 2.2 |
| Varian OBI (Ding <i>et al</i> ) [60] | 1 - 5          | 3 - 9         | 2 - 9     |

# Imaging doses (CBCT)

Review paper

Imaging dose from cone beam computed tomography in radiation therapy

Parham Alaei <sup>a,\*</sup>, Emiliano Spezi <sup>b,c</sup>

<sup>a</sup> University of Minnesota, Minneapolis, MN, USA

<sup>b</sup> School of Engineering, Cardiff University, Cardiff, Wales, UK

<sup>c</sup> Velindre Cancer Centre, Cardiff, Wales, UK

| Kilovoltage<br>CBCT | Manufacturer (Version,<br>if specified) | kVp | mAs/acquisition | Phantom type                     | Dosimeter      | Dose in phantom/<br>fraction (cGy) |
|---------------------|-----------------------------------------|-----|-----------------|----------------------------------|----------------|------------------------------------|
| Sykes [18]          | Elekta XVI (v3.1)                       | 130 | 0.56            | Rando head                       | TLD            | 1.9–2.9                            |
| Islam [20]          | Elekta XVI                              | 100 | 2               | Cylindrical (16 & 30 cm dia.)    | Chamber        | 0.7–3.5                            |
|                     |                                         | 120 | 2               |                                  |                |                                    |
|                     |                                         | 140 | 2               |                                  |                |                                    |
| Amer [21]           | Elekta XVI                              | 100 | 0.1             | Rando head                       | TLD            | 0.13                               |
|                     |                                         | 120 | 0.4             | Rando chest                      |                | 0.72                               |
|                     |                                         | 130 | 1.2             | Rando pelvis                     |                | 2.1                                |
| Wen [22]            | Varian OBI                              | 125 | 2               | Rando pelvis                     | TLD            | 2.1–4.7                            |
| Kan [6]             | Varian OBI                              | 125 | 2               | Female Rando head, chest, pelvis | TLD            | 3.6–6.7                            |
|                     |                                         | 125 | 0.4             |                                  |                |                                    |
| Osei [25]           | Varian OBI                              | 125 | 2               | Rando pelvis                     | TLD            | 3.0–11.5                           |
| Winey [26]          | Varian OBI                              | 125 | 1.6             | CIRS Thorax                      | Chamber/OSL    | 2.4–9.1                            |
| Marinello [27]      | Varian OBI                              | 125 | 2               | Rando                            | TLD/Gafchromic | 4.7–6.2                            |
| Tomic [29]          | Varian OBI (v1.4)                       | 100 | 0.2             | Rando head, chest, pelvis        | Gafchromic     | 0.1–4.7 (surface)                  |
|                     |                                         | 100 | 0.4             |                                  |                |                                    |
|                     |                                         | 100 | 1.6             |                                  |                |                                    |
|                     |                                         | 125 | 1.04            |                                  |                |                                    |
|                     |                                         | 125 | 1.6             |                                  |                |                                    |
| Tomic [30]          | Varian OBI (v1.4)                       | 100 | 0.2             | Rando head, chest, pelvis        | Gafchromic     | 0.03–2.8 (surface)                 |
|                     |                                         | 100 | 0.4             |                                  |                |                                    |
|                     |                                         | 100 | 1.6             |                                  |                |                                    |
|                     |                                         | 125 | 1.04            |                                  |                |                                    |
|                     |                                         | 125 | 1.6             |                                  |                |                                    |
| Hyer [31]           | Varian OBI (v1.4)                       | 100 | 0.4             | Male Anthro head, chest, pelvis  | Scintillator   | 0.2–2.8                            |
|                     |                                         | 110 | 0.4             |                                  |                |                                    |
|                     |                                         | 125 | 1.04            |                                  |                |                                    |
|                     | Elekta XVI (v.4)                        | 100 | 0.1             |                                  |                | 0.1–2.9                            |
|                     |                                         | 120 | 1.6             |                                  |                |                                    |
|                     |                                         | 120 | 2.56            |                                  |                |                                    |
| Palm [32]           | Varian OBI (v1.3)                       | 125 | 0.4             | Female Rando head, chest, pelvis | TLD            | 8.7–13                             |
|                     |                                         | 125 | 2               |                                  |                |                                    |
|                     | Varian OBI (v1.4)                       | 125 | 1.04            |                                  |                | 0.25–3.42                          |
|                     |                                         | 125 | 2               |                                  |                |                                    |
|                     |                                         | 100 | 0.2             |                                  |                |                                    |
|                     |                                         | 100 | 0.4             |                                  |                |                                    |
|                     |                                         | 100 | 2               |                                  |                |                                    |



# Imaging doses (MVCT)

## MSAD: MultiSlice Average dose

### Evaluation of MVCT imaging dose levels during helical IGRT: comparison between ion chamber, TLD, and EBT3 films

Jean-Pierre Mege,<sup>1a</sup> Sun Wenzhao,<sup>2</sup> Attila Veres,<sup>3</sup> Guillaume Auzac,<sup>1</sup>  
Ibrahima Diallo,<sup>4</sup> Dimitri Lefkopoulos<sup>1</sup>

Table 3. MSAD (for 1 MVCT) evaluated with radiochromic films for three anatomical regions (ATOM phantom) and comparison with the doses obtained in the cylindrical phantom. For comparison, results obtained by Shah et al.<sup>(33)</sup> for different localizations.

|                                    | Our Measurements |           |           | Shah <sup>(33)</sup> |
|------------------------------------|------------------|-----------|-----------|----------------------|
|                                    | Fine             | Normal    | Coarse    | Normal Mode          |
| Head & Neck                        |                  |           |           |                      |
| Average MSAD (cGy)                 | 3.9±0.3          | 2.1±0.2   | 1.4±0.1   | 1.45                 |
| MSAD range                         | [3.5-4.5]        | [1.5-2.7] | [1-1.8]   | (parotids)           |
| Maximal dose / Central dose        | 1.15             | 1.3       | 1.3       | 1.2                  |
| Thorax                             |                  |           |           |                      |
| Average MSAD (cGy)                 | 3.5±0.3          | 2±0.2     | 1.3±0.1   | 1.14                 |
| MSAD range                         | [3 - 4.1]        | [1.5-2.6] | [0.9-2.1] | (lungs)              |
| Maximal dose / Central dose        | 1.17             | 1.3       | 1.6       | 1.44                 |
| Abdomen                            |                  |           |           |                      |
| Average MSAD (cGy)                 | 3.3±0.3          | 1.7±0.2   | 1.2±0.1   | 1.05                 |
| MSAD range                         | [2.8-4.1]        | [1.3-2.3] | [0.7-1.9] | (bladder)            |
| Maximal dose / Central dose        | 1.24             | 1.35      | 1.6       | 1.25                 |
| Cylindrical phantom $\phi$ = 30 cm |                  |           |           |                      |
| MSAD <sub>w</sub> (cGy)            | 3                | 1.5       | 1.1       | 1.06                 |
| Maximal dose / Central dose        | 1.26             | 1.21      | 1.5       | 1.08                 |

Under certain conditions, the MSAD is  
approximately equivalent to CTDI<sub>vol</sub>



# Global comparison

## Assessment of image quality and dose calculation accuracy on kV CBCT, MV CBCT, and MV CT images for urgent palliative radiotherapy treatments

Mareike Held,<sup>1</sup> Florian Cremers,<sup>2</sup> Penny K. Sneed,<sup>1</sup> Steve Braunstein,<sup>1</sup> Shannon E. Fogh,<sup>1</sup> Jean Nakamura,<sup>1</sup> Igor Barani,<sup>1</sup> Angelica Perez-Andujar,<sup>1</sup> Jean Pouliot,<sup>1</sup> and Olivier Morin<sup>1a</sup>  
 Department of Radiation Oncology,<sup>1</sup> University of California San Francisco, CA, USA;  
 Department of Radiation Oncology,<sup>2</sup> Universitätsklinikum Schleswig-Holstein, Lübeck, Germany  
 Olivier.Morin@ucsf.edu

Received 2 September, 2015; accepted 18 November, 2015

TABLE 2. Image dose, noise, CNR, uniformity, and spatial resolution.

|                    | $CTDI_{vol}$<br>(cGy)<br>$rFOV/eFOV$ | Noise | CNR<br>(bone/water) | Uniformity | Spatial<br>Resolution<br>50% cf (1/cm) |
|--------------------|--------------------------------------|-------|---------------------|------------|----------------------------------------|
| kV CT (MX 8000)    | 0.20                                 | 0.53  | 161.5               | 0.1        | 4.1                                    |
| kV CBCT (TrueBeam) | 0.29/1.43 <sup>a</sup>               | 2.10  | 52.2                | -1.0       | 4.1                                    |
| kV CBCT (Versa)    | 0.12/2.20 <sup>a</sup>               | 3.07  | 36.7                | 6.7        | 2.1                                    |
| MV CBCT (Artiste)  | 5.00/15.00 <sup>b</sup>              | 1.91  | 14.9                | -4.5       | 1.6                                    |
| MV CT (Tomo)       | ~ 2.00 <sup>b</sup>                  | 3.14  | 15.7                | 0.0        | 2.1                                    |

<sup>a</sup>  $CTDI_w$ , <sup>b</sup> dose


$CTDI_{vol} = CTDI_w / \text{pitch}$

Contrast to noise ratio

rFOV = regular FOV  
 eFOV = extended FOV

# Rough comparison of imaging systems

+ means better  
- means worse





# Why do we need image quantification?


Having the imager on-board enables image acquisition in treatment position

This is a fantastic opportunity to estimate dose distributions in the patient using the most up-to-date anatomical data. It could enable **on-line** and **off-line** adaptive strategies. In such strategies, the quality of the image is an **essential** piece of the workflow


For computing dose distributions, accurate conversion of imaging data into physical quantities must be performed. We need to predict for every tissue:

- The attenuation of the photons for high energy X-rays
- The deceleration rate for high energy protons

# Use of plastic inserts of known compositions and densities to calibrate the CT



# A new comer: dual energy CT calibration



**Comprehensive analysis of proton range uncertainties related to patient stopping-power-ratio estimation using the stoichiometric calibration**

Ming Yang<sup>1,2</sup>, X Ronald Zhu<sup>1,2</sup>, Peter C Park<sup>1,2</sup>, Uwe Titt<sup>1,2</sup>,  
Radhe Mohan<sup>1,2</sup>, Gary Virshup<sup>3</sup>, James E Clayton<sup>3</sup> and Lei Dong<sup>1,2,4</sup>

<sup>1</sup> Department of Radiation Physics, Unit 94, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

<sup>2</sup> Medical Physics Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, 7000 Fannin St, Houston, TX 77030, USA

<sup>3</sup> Ginzton Technology Center, Varian Medical Systems, 3120 Hansen Way, Palo Alto, CA 94303, USA

There is no unicity between HU and atomic composition for a given CT energy. By acquiring images with several energies, it is possible to better characterize the tissues

There are multiple methods to convert DECT into quantities of interest

## CBCT is not a good natural image quantifier

**CBCT quantification** depends on a number of parameters and issues, among which:

- Image acquisition parameters
- Image artefacts due to scatter, scanned object size, and number of projections

# Take home messages

Imaging has three main functions in RT:

1. For delineating contours and organs-at-risk → **Visual quality!**
2. For computing the dose distributions → **Quantitative quality!**
3. For reducing uncertainties (positioning uncertainties, motion model, trigger replanning if necessary, ...) → **Practical requirements (on-board, fast, ...)**





# What are the specificities of QA of imaging devices in radiotherapy?

## What applies to radiology AND:

- Positioning consistency must be well ensured at all times → lasers placed for positioning must reflect actual position in the scanner
- For on-board imagers, the isocenter of the imaging device must remain aligned with the isocenter of the treatment device
- Geometrical distances must be consistent with baseline
- Image quantification must be properly checked, with a frequency and tolerances adapted to the device considered

# QA protocols

## Quality assurance for image-guided radiation therapy utilizing CT-based technologies: A report of the AAPM TG-179

Jean-Pierre Bissonnette<sup>a)</sup>  
Task Group 179, Department of Radiation Physics, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada, M5G 2M9

Peter A. Balter and Lei Dong  
Department of Radiation Physics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030

Katja M. Langen  
Department of Radiation Oncology, M. D. Anderson Cancer Center Orlando, Orlando, Florida 32806

D. Michael Lovelock  
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Moyed Miften  
Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado 80045

Douglas J. Moseley  
Department of Radiation Physics, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada, M5G 2M9

Jean Pouliot  
Department of Radiation Oncology, UCSF Comprehensive Cancer Center, 1600 Divisadero St., Suite H 1031, San Francisco, California 94143-1708

Jan-Jakob Sonke  
Department of Radiation Oncology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Sua Yoo  
Department of Radiation Oncology, Duke University, Durham, North Carolina 27710



IAEA HUMAN HEALTH SERIES

No. 19

Quality Assurance  
Programme for Computed  
Tomography: Diagnostic  
and Therapy Applications



IAEA  
International Atomic Energy Agency

## A quality assurance program for image quality of cone-beam CT guidance in radiation therapy

Jean-Pierre Bissonnette,<sup>a)</sup> Douglas J. Moseley, and David A. Jaffray  
Radiation Medicine Program, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada



Contents lists available at ScienceDirect

Physica Medica

journal homepage: <http://www.physicamedica.com>



ORIGINAL PAPER

### Quality control in cone-beam computed tomography (CBCT) EFOMP-ESTRO-IAEA protocol (summary report)



Hugo de las Heras Gala<sup>a,\*</sup>, Alberto Torresin<sup>b</sup>, Alexandru Dasu<sup>c,d</sup>, Osvaldo Rampado<sup>e</sup>, Harry Delis<sup>f</sup>, Irene Hernández Girón<sup>g</sup>, Chrysoula Theodorakou<sup>h</sup>, Jonas Andersson<sup>i</sup>, John Holroyd<sup>j</sup>, Mats Nilsson<sup>k</sup>, Sue Edyvean<sup>l</sup>, Vesna Gershan<sup>m</sup>, Lama Hadid-Beurrier<sup>n</sup>, Christopher Hoog<sup>o</sup>, Gregory Delpon<sup>p</sup>, Ismael Sancho Kolster<sup>q</sup>, Primož Peterlin<sup>r</sup>, Julia Garayoa Roca<sup>s</sup>, Paola Caprile<sup>t</sup>, Costas Zervides<sup>u,v</sup>

## QA FOR RT SUPPLEMENT

### QUALITY ASSURANCE FOR THE GEOMETRIC ACCURACY OF CONE-BEAM CT GUIDANCE IN RADIATION THERAPY

JEAN-PIERRE BISSONNETTE, PH.D., DOUG MOSELEY, PH.D., ELIZABETH WHITE, B.SC.,  
MICHAEL SHARPE, PH.D., TOM PURDIE, PH.D., AND DAVID A. JAFFRAY, PH.D.

Radiation Medicine Program, Princess Margaret Hospital, Toronto, Ontario, Canada

The introduction of volumetric X-ray image-guided radiotherapy systems allows improved management of geometric variations in patient setup and internal organ motion. As these systems become a routine clinical modality, we propose a daily quality assurance (QA) program for cone-beam computed tomography (CBCT) integrated with a linear accelerator. The image-guided system used in this work combines a linear accelerator with conventional X-ray tube and an amorphous silicon flat-panel detector mounted orthogonally from the accelerator central beam axis. This article focuses on daily QA protocols germane to geometric accuracy of the CBCT systems and proposes tolerance levels on the basis of more than 3 years of experience with seven CBCT systems used in our clinic. Monthly geometric calibration tests demonstrate the long-term stability of the flex movements, which are reproducible within  $\pm 0.5$  mm (95% confidence interval). The daily QA procedure demonstrates that, for rigid phantoms, the accuracy of the image-guided process can be within 1 mm on average, with a 99% confidence interval of  $\pm 2$  mm. © 2008 Elsevier Inc.

# CBCT QA



Contents lists available at ScienceDirect

Physica Medica

journal homepage: <http://www.physicamedica.com>



ORIGINAL PAPER

Quality control in cone-beam computed tomography (CBCT)  
EFOMP-ESTRO-IAEA protocol (summary report)



Hugo de las Heras Gala<sup>a,\*</sup>, Alberto Torresin<sup>b</sup>, Alexandru Dasu<sup>c,d</sup>, Osvaldo Rampado<sup>e</sup>, Harry Delis<sup>f</sup>, Irene Hernández Girón<sup>g</sup>, Chrysoula Theodorakou<sup>h</sup>, Jonas Andersson<sup>i</sup>, John Holroyd<sup>j</sup>, Mats Nilsson<sup>k</sup>, Sue Edyvean<sup>l</sup>, Vesna Gershan<sup>m</sup>, Lama Hadid-Beurrier<sup>n</sup>, Christopher Hoog<sup>o</sup>, Gregory Delpon<sup>p</sup>, Ismael Sancho Kolster<sup>q</sup>, Primož Peterlin<sup>r</sup>, Julia Garayoa Roca<sup>s</sup>, Paola Caprile<sup>t</sup>, Costas Zervides<sup>u,v</sup>

**Table 1**

Summary of recommended image quality tests.

| Parameter                   | Procedures                                           | Frequency <sup>*</sup> |                          |                                           | Action level                                              |                                                                  |                                |
|-----------------------------|------------------------------------------------------|------------------------|--------------------------|-------------------------------------------|-----------------------------------------------------------|------------------------------------------------------------------|--------------------------------|
|                             |                                                      | Dental                 | Interventional radiology | Radiotherapy                              | Dental                                                    | Interventional rad.                                              | Radiotherapy                   |
| 3.1 Uniformity              | XYZ uniformity curves                                | Annual                 |                          | Monthly                                   | Manufacturer specifications, or >10% difference air water |                                                                  | Deviation from baseline >10 HU |
| 3.2 Geometrical precision   | DIN method                                           | Annual (or none)       | (not relevant)           | Monthly (coincidence of isocentres daily) | Uniformity parameter U < 5                                |                                                                  |                                |
|                             | Geometrical accuracy                                 |                        |                          |                                           | >1 mm                                                     | >2 mm                                                            | >2 mm for conventional         |
|                             | Spatial Stability                                    |                        |                          |                                           | (not relevant)                                            | (not relevant)                                                   | treatments, >1 mm for SRS/SBRT |
| 3.3 Voxel density values    | Voxel values for different materials                 | Annual                 |                          | Monthly                                   | Manufacturer specifications, or >25% difference air water | Deviations >50 HU from the baseline value (still under research) |                                |
| 3.4 Noise                   | ROI standard deviation                               | Annual                 |                          | Monthly                                   | Differences from baseline >20%                            |                                                                  |                                |
| 3.5 Low contrast resolution | Contrast-to-noise ratio                              | Annual                 |                          |                                           | Differences from baseline >40%                            |                                                                  |                                |
| 3.6 Spatial resolution      | Frequency at 10% of the modulation transfer function | Annual                 |                          |                                           | Acceptance indicator <100 <sup>§</sup>                    |                                                                  |                                |
|                             |                                                      |                        |                          |                                           | <10 lp/cm (high resolution mode)                          | <5 lp/cm                                                         |                                |

\* Depending on the complexity of the treatment techniques used and the weight of CBCT for image guidance, the monthly tests in radiotherapy facilities may be carried out quarterly or every half a year. In addition to the indicated frequency, the tests should be performed at acceptance of the device as well as after maintenance work or upgrades that could affect the integrity of the system.

# CBCT QA



Contents lists available at ScienceDirect

Physica Medica

journal homepage: <http://www.physicamedica.com>




ORIGINAL PAPER

Quality control in cone-beam computed tomography (CBCT)  
EFOMP-ESTRO-IAEA protocol (summary report)



Hugo de las Heras Gala<sup>a,\*</sup>, Alberto Torresin<sup>b</sup>, Alexandru Dasu<sup>c,d</sup>, Osvaldo Rampado<sup>e</sup>, Harry Delis<sup>f</sup>, Irene Hernández Girón<sup>g</sup>, Chrysoula Theodorakou<sup>h</sup>, Jonas Andersson<sup>i</sup>, John Holroyd<sup>j</sup>, Mats Nilsson<sup>k</sup>, Sue Edyvean<sup>l</sup>, Vesna Gershan<sup>m</sup>, Lama Hadid-Beurrier<sup>n</sup>, Christopher Hoog<sup>o</sup>, Gregory Delpon<sup>p</sup>, Ismael Sancho Kolster<sup>q</sup>, Primož Peterlin<sup>r</sup>, Julia Garayoa Roca<sup>s</sup>, Paola Caprile<sup>t</sup>, Costas Zervides<sup>u,v</sup>




**Fig. 2.** An example of the measurement of uniformity (a), geometrical linearity (b), density values or Hounsfield units (c), noise (d), contrast-to-noise ratio (e) and modulation transfer function (f).

# CBCT QA


## A quality assurance program for image quality of cone-beam CT guidance in radiation therapy

Jean-Pierre Bissonnette,<sup>a)</sup> Douglas J. Moseley, and David A. Jaffray  
*Radiation Medicine Program, Princess Margaret Hospital, 610 University Avenue, Toronto,  
Ontario M5G 2M9, Canada*




(a)

Images acquired with volumetric CT showing the definition of QA metrics used to analyze image quality. A) Image of the CatPhan phantom. C) Verification of image scale. D) Assessment of image uniformity.



(c)



(d)

# CBCT QA

## A quality assurance program for image quality of cone-beam CT guidance in radiation therapy

Jean-Pierre Bissonnette,<sup>a)</sup> Douglas J. Moseley, and David A. Jaffray  
*Radiation Medicine Program, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada*

TABLE I. Recommended image quality QA for a kilovoltage imaging system mounted on an accelerator. Tolerances and frequency may change according to expectations, experience, and performance. Tests denoted with an asterisk indicate minimal tests required after replacing system components.

| Frequency                          | Procedure                                                                                                                                                                                                                   | Tolerance                                                                                                   |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Daily or<br>each use               | Detector stability and system performance<br>Dark image calibration acquisition before each scan                                                                                                                            |                                                                                                             |
| Six-monthly or<br>after<br>service | Imaging system performance<br>Gain stability*<br>Defect maps*<br>Image quality<br>Scale and distances*<br>Uniformity<br>High contrast spatial resolution*<br>CT number accuracy<br>Low contrast detectability<br>Artifacts* | Replace/refresh<br>Replace/refresh<br><br>$\pm 1$ mm<br>Baseline<br>2 mm<br>Baseline<br>Baseline<br>Absence |
| Annual or<br>after service         | Review of daily and monthly test results                                                                                                                                                                                    | Complete                                                                                                    |






# Dose sculpting: spatial differentiation between normal tissue and tumor

**Cancer:**

*“Malignant process involving unregulated cell growth”*



Goals of radiotherapy:


**Eradicate/Damage the Tumor**

**Save/Spare the healthy  
surrounding tissue**

# Dose sculpting: spatial differentiation between normal tissue and tumor

**Cancer:**

*"Malignant process involving unregulated cell growth"*





Goals of radiotherapy:

**Eradicate/Damage the Tumor**

**Save/Spare the healthy surrounding tissue**


*"Shaping" of the beam with a multi-leaf collimator*



# Dose sculpting: spatial differentiation between normal tissue and tumor

**Cancer:**

*"Malignant process involving unregulated cell growth"*





Goals of radiotherapy:


**Eradicate/Damage the Tumor**

**Save/Spare the healthy surrounding tissue**

*"Shaping" of the beam with a multi-leaf collimator*




*Multiple beam orientations, coinciding in the tumor*




# Intensity modulation

## "Classical" Conformation




## Intensity Modulation




# Evolution of delivery techniques of the last 20 years

*Classic Radiotherapy*




*Highly conformal Radiotherapy*





*“Dose sculpting hitting the target avoiding other tissues”*






Autoportrait par Georges Chicotot (1908)<sup>78</sup>

# Going beyond intensity-modulation




Conventional radiotherapy techniques employ photon beams to treat tumors.



Protons offer a more advantageous depth-dose profile.








# A modulator wheel produces the SOBP




The spread-out Bragg peak (SOBP) :

$$S(z) = \sum_{i=1}^N w_i D_i(z)$$




## Advantages of proton beams



# How do we deliver protons?


Collimator



## Typical installation: inside the treatment room




## Typical installation: behind the walls...






## Pencil beam scanning




# Dose sculpting




# Proton therapy physics in a nutshell


- Important interaction mechanisms for **heavy particles**
  - (Inelastic) collisions with bound atomic electrons (a)
  - Elastic scattering (b)
  - Nuclear interactions (c)






**Inelastic collisions with bound atomic electrons are the main cause of the deceleration of the protons, which leads to the stopping powers**




**Elastic scattering with target nuclei is the main reason why protons do not travel straight**







# Physics of nuclear reactions

## Nuclear inelastic




# Emission of secondary particles (multiplicity)







# Effect on incident particle fluence





**Figure 3.** Relative fraction of the fluence  $\Phi$  in a broad beam of protons remaining as a function of depth  $z$  in water. The gradual depletion of protons from entrance to near the end of range is caused by removal of protons from nuclear reactions. The rapid falloff in the number of protons near the end of range is caused by ions running out of energy and being absorbed by the medium. The sigmoid shape of the distal falloff is caused by range straggling or by stochastic fluctuations in the energy loss of individual protons.

# Effect on depth-dose distribution



# Effect on depth-dose distribution





## Physical neutron dose

- Maximum 1% of therapeutic Gy for passive systems
- Of order of 0.1% for active systems
- Estimated in Paganetti et al 2012 to less than 0.04% (excluding the delivery system)
- !! Needs to be scaled by a proper weighting factor which can be great for neutrons!!

**Figure 4.** Depth-dose distributions (Bragg peak normalized to 100%) for a 160 MeV proton beam incident on a water phantom. The upper figure shows the total dose and the dose due to primary and secondary protons. The lower figure compares, on a logarithmic scale, the doses due to different types of particles (solid lines: primary p, secondary  $\alpha$  and d; dashed lines: secondary p,  $^3\text{He}$ , t). A vertical line indicates the position of the maximum of the Bragg peak.

# Effect on depth-dose distribution



**Figure 5.** Depth-dose distributions for a modulated 160 MeV proton beam incident on a water phantom in linear scale (upper figure) and in a logarithmic scale showing the contributions of light and heavier secondaries. The dose is laterally summed to the limits of the dose plateau ( $\pm 3$  cm).

## Physical neutron dose

- Maximum 1% of therapeutic Gy for passive systems
- Of order of 0.1% for active systems
- Estimated in Paganetti et al 2012 to less than 0.04% (excluding the delivery system)
- !! Needs to be scaled by a proper weighting factor which can be great for neutrons!!



# Physics of nuclear reactions: take-home messages

Nuclear reactions cause an attenuation of the primary fluence

Secondary particles ejected are mostly protons and neutrons

Only protons contribute significantly to the dose at moderate distances

Neutrons have low relevance for radiotherapy, but are very important for radioprotection



# Radiation protection aspects in proton therapy

**Prompt radiation** (exposure to staff/public)

**Delayed radiation** (due to activation):


- Exposure of (maintenance) personnel
  - Procedures/personal dose monitoring
- Emissions to environment can lead to exposure of public
  - Disposal of activated waste, room ventilation

# Concept of equivalent dose

**Equivalent dose** = absorbed dose \* radiation weighting factor ( $W_R$ ) in Sievert (Sv)

| Type                                      | Energy range   | $W_R$                               |
|-------------------------------------------|----------------|-------------------------------------|
| Photons, electrons                        | all            | 1                                   |
| Neutrons                                  | < 1 MeV        | $2.5 + 18.2\exp[-(\ln(E))^2/6]$     |
|                                           | 1 MeV - 50 MeV | $5.0 + 17.0\exp[-(\ln(2E))^2/6]$    |
|                                           | > 50 MeV       | $2.5 + 3.25\exp[-(\ln(0.04E))^2/6]$ |
| Protons                                   |                | 2                                   |
| Alpha, fission fragments,<br>heavy nuclei | all            | 20                                  |

## Radiation weighting factor for neutrons





# Basics of radiation protection in PT (neutron irradiation)


Neutrons have a stronger radiobiological effect than X-rays for a same physical dose

They have complex physics of transport in matter. Hydrogen interacts a lot with neutrons. Therefore, materials enriched with hydrogen are very welcome for shielding

# **Radiation protection in proton therapy: practical matters**

# Two main configurations of IBA system

*Proteus***PLUS**




One Isochronous Cyclotron  
One Energy Selection System  
+ Multiple Rooms (different types)  
+ Multiple Beam Delivery Techniques

*Proteus***ONE**



One synchro-cyclotron  
One Energy Selection System  
One Room  
One Beam Delivery Technique

# Radiation sources in Proteus One (machine foreseen in Leuven and Charleroi)



Energy selection system (degrader + collimator + slits) common to all cyclotron-based systems


# Radiation protection questions in proton therapy

- For staff:
  - What is the shielding necessary to obey Belgian law?
- For patients
  - What is the dose due to secondary radiation like neutrons, either coming from machine elements, or the patient itself?


# Radiation protection questions in proton therapy

- For staff:
  - What is the shielding necessary to obey Belgian law?
- For patients
  - What is the dose due to secondary radiation like neutrons, either coming from machine elements, or the patient itself?

# Shielding design for proton therapy facilities



# Shielding design for proton therapy facilities





# Simulation of shielding design for proton therapy facilities

- Complex task:
  - Multiple sources with different target materials and beam energies;
  - Neutron attenuation properties vary with direction and concrete depth;
  - Complex geometries with thick barriers and mazes.
- Assumptions needed for simulating the amount of shielding needed:
  - Facility drawings
  - Radiation sources and beam losses (vs. Beam energy)
  - Patient case mix:
    - Clinical activities
    - QA activities
    - Maintenance activities
  - Dose limits in public/controlled areas:
    - Yearly dose rates
    - Hourly dose rates
    - Instantaneous dose rates

# Mazes should have a smart design

- Radiation at maze entrance consists of neutrons that scatter through the maze
- Forward-directed radiation from target should never be aimed toward the maze opening
- Sum of thicknesses of each maze wall should equal thickness of the direct-shielded wall
- As number of legs increases, the attenuation increases
- The legs should be perpendicular to each other
- Reducing maze cross-section area reduces dose at entrance
- At least two scatters are desirable






Fig. 3. Neutron measurement positions inside and around the FBTR.

# Mazes should have a smart design




Good maze



Bad maze

# Proteus ONE modeling (machine in Leuven and foreseen in Charleroi)



## Proteus<sup>®</sup>ONE (machine in Leuven and foreseen Charleroi) : Annual Dose Determination

- The annual dose determination around the *Proteus<sup>®</sup>ONE* vault is based upon a realistic patient case mix established by IBA clinical director and based upon our experience in PT treatments.
- This *Proteus<sup>®</sup>ONE* patient case mix is based upon the following usage:
  - Clinical Operation = 4800 hours/year
    - 16 hours/day (2 shifts)
    - 6 days/week
    - 50 weeks/year
  - Patients treated per year = 435
  - Fractions (2 Gy) per year = 16660
- The yearly fractions are divided into 4 major types of indications corresponding to groups of tumors.
- The model also include fractions devoted to QA activities (morning QA and patient QA).

# Annual Patient Case Mix



Utilisation de la machine pour obtenir 1Gy (courant de protons x temps d'irradiation)

Utilisation effective de la machine pour 1h de traitement (tout compris (positionnement, prise en charge...))

Clinical Activities  
QA Activities

| Indications   | Min. Range (g/cm <sup>2</sup> ) | Max. Range (g/cm <sup>2</sup> ) | Field size (cm <sup>2</sup> ) | Annual Dose (Gy) | w(1Gy) (nA.s) | w <sub>iso</sub> (nA.h) |
|---------------|---------------------------------|---------------------------------|-------------------------------|------------------|---------------|-------------------------|
| Head & Neck   | 8                               | 18                              | 7.7 x 7.7                     | 5090             | 7.29          | 10.31                   |
|               | 2                               | 12                              | 7.7 x 7.7                     | 5090             | 6.27          | 8.87                    |
| Lung Tumor    | 8                               | 20                              | 7.9 x 7.9                     | 4307             | 8.39          | 10.04                   |
|               | 4                               | 17                              | 7.9 x 7.9                     | 4307             | 8.36          | 10.01                   |
| Sarcoma       | 20                              | 32                              | 10.1 x 10.1                   | 5612             | 15.42         | 24.04                   |
|               | 15                              | 27                              | 10.1 x 10.1                   | 5612             | 14.89         | 23.22                   |
| Pediatric     | 8                               | 18                              | 18.6 x 18.6                   | 1653             | 42.09         | 19.33                   |
|               | 2                               | 12                              | 18.6 x 18.6                   | 1653             | 36.46         | 16.74                   |
| QA – low R    | 4                               | 14                              | 10 x 10                       | 1200             | 12.04         | 4.013                   |
| QA – medium R | 13                              | 23                              | 10 x 10                       | 1200             | 13.78         | 4.593                   |
| QA – high R   | 22                              | 32                              | 10 x 10                       | 1200             | 15.75         | 5.250                   |

# Proteus®ONE Annual dose rates





| Position | Barrier thickness (m) | Max. H*(10) (μSv/year) |
|----------|-----------------------|------------------------|
| A        | 2.8                   | 392.2                  |
| B        | 2.0                   | 148.5                  |
| C        | 1.8 to 2.4            | 275.5                  |
| D        | 1.4 to 2.0            | 108.0                  |
| E        | 2.0                   | 325.2                  |
| F        | 2.8                   | 347.9                  |
| G        | 2.8                   | 397.8                  |
| H        | 2.5                   | 390.2                  |
| I        | 1.9                   | 233.4                  |
| J        | 2.1                   | 356.6                  |

# Radiation protection questions in proton therapy

- For staff:
  - What is the shielding necessary to obey Belgian law?
- For patients
  - What is the dose due to secondary radiation like neutrons, either coming from machine elements, or the patient itself?



# Effect on depth-dose distribution





## Physical neutron dose

- Maximum 1% of therapeutic Gy for passive systems
- Of order of 0.1% for active systems
- Estimated in Paganetti et al 2012 to less than 0.04% (excluding the delivery system)
- !! Needs to be scaled by a proper RBE which can be great for neutrons!!

**Figure 4.** Depth-dose distributions (Bragg peak normalized to 100%) for a 160 MeV proton beam incident on a water phantom. The upper figure shows the total dose and the dose due to primary and secondary protons. The lower figure compares, on a logarithmic scale, the doses due to different types of particles (solid lines: primary p, secondary  $\alpha$  and d; dashed lines: secondary p,  $^3\text{He}$ , t). A vertical line indicates the position of the maximum of the Bragg peak.

# Effect on depth-dose distribution



**Figure 5.** Depth-dose distributions for a modulated 160 MeV proton beam incident on a water phantom in linear scale (upper figure) and in a logarithmic scale showing the contributions of light and heavier secondaries. The dose is laterally summed to the limits of the dose plateau ( $\pm 3$  cm).

## Physical neutron dose

- Maximum 1% of therapeutic Gy for passive systems
- Of order of 0.1% for active systems
- Estimated in Paganetti et al 2012 to less than 0.04% (excluding the delivery system)
- !! Needs to be scaled by a proper RBE which can be great for neutrons!!

# Activation of materials

- Neutrons can activate materials
- Recommendations for handling “hot” materials (i.e. phantom that has just been irradiated for long time)
- Recommendations for keeping distance with nozzle and collimation parts

# Conclusions

- Interactions of proton beams with matter generate complex fields of secondary neutrons and photons.
- Monte Carlo simulation codes are an ideal tool to address the radiation protection challenges created by this new kind of cancer therapy:
  - Shielding design around the equipment
  - Out-of-field radiation doses to patient

Thank you!